ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Performance Based

<< Previous

Bullboard Posts

Next >>

Comment by M101on May 25, 2024 6:53pm

122 Views

Post# 36057634

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Performance Based

It's past-time for the company to drop some rumour that it's working on an anti-310 mab, a targeted dementia bioweapon fully funded by fauci/CIA/Pfizer immune from public disclosure. That would get the share price moving, unless Fauci gets nailed by congress, but what's the chance of that?

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China